Structural Basis of Transcription Inhibition by Fidaxomicin (Lipiarmycin A3)

Volume: 70, Issue: 1, Pages: 60 - 71.e15
Published: Mar 29, 2018
Abstract
Fidaxomicin is an antibacterial drug in clinical use for treatment of Clostridium difficile diarrhea. The active ingredient of fidaxomicin, lipiarmycin A3 (Lpm), functions by inhibiting bacterial RNA polymerase (RNAP). Here we report a cryo-EM structure of Mycobacterium tuberculosis RNAP holoenzyme in complex with Lpm at 3.5-Å resolution. The structure shows that Lpm binds at the base of the RNAP “clamp.” The structure exhibits an open...
Paper Details
Title
Structural Basis of Transcription Inhibition by Fidaxomicin (Lipiarmycin A3)
Published Date
Mar 29, 2018
Volume
70
Issue
1
Pages
60 - 71.e15
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.